LGND Related FDA
-
Ligand Pharmaceuticals (LGND) Agreement with Merck KGaA Unit Terminated
-
FDA Accepts Pfizer (PFE) Ligand (LGND) NDA For Bazedoxifene/Conjugated Estrogens
-
Ligand Pharma (LGND) to resume trading at 9:45AM after FDA approval
-
Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients
-
Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report
-
Griffin Securities Reiterates a 'Buy' on Ligand Pharma (LGND); Investors Jumped The Gun...Attractive Opportunity
-
Ligand (LGND) Partner GlaxoSmithKline (GSK) Granted Priority Review for Promacta
-
Cantor Fitzgerald Maintains a 'Buy' on Ligand Pharma (LGND); Key Partnered Drug is Approved
-
UPDATE: Onyx Pharmaceuticals (ONXX) Kyprolis approved
-
Ligand Pharma (LGND) Pops Higher Ahead of FDA Committee Vote for Carfilzomib (ONXX)
-
Ligand Pharma (LGND) Reports Encouraging Preclinical Data for LGD-6972 as Type 2 Diabetes Treatment
-
Ligand Pharmaceuticals (LGND) Says Glaxo (GSK) Submits Regulatory Apps for Promacta/Revolade
-
Ligand (LGND) Licenses DARA to Retrophin; May Get Up to $75M in Milestone Payments
-
Ligand Pharma (LGND) Completes PG-Free Melphalan Phase II, Issues Update
-
Ligand (LGND) Unit Enters $3M Captisol Supply Agreement with Hospira (HSP)
-
Ligand Pharma (LGND) Reports Melphalan Met All Endpoints in Phase II Study
-
Ligand Pharmaceuticals (LGND) Partner GlaxoSmithKline (GSK) Receives Positive Data from Promacta PIII ENABLE1 Study
-
Ligand Pharma (LGND) Licenses Captisol-Enabled Clopidogrel from The Medicines Co. (MDCO)
-
Ligand Pharma (LGND) Announces Glaxo (GSK) Receives O.K. in Japan for Revolade
-
Ligand Pharma (LGND) Announces Launch of Viviant in Japan (PFE)
-
Ligand Pharma (LGND) To Receive $6.5M Milestone Payment from Roche (RHHBY)
-
Ligand Pharma (LGND) Announces that Glaxo (GSK) was Approved for Revolade Marketing in Europe
-
Ligand Pharma (LGND) Partner Glaxo (GSK) Receives Positive Opinion for Revolade from CHMP
-
Ligand Pharmaceuticals (LGND) and Pfizer (PFE) Receive EC Approval for FABLYN
-
Ligand Pharma (LGND) Partner GlaxoSmithKline's Granted Accelerated Approval of PROMACTA
-
Ligand Pharmaceuticals (LGND) Partner GlaxoSmithKline (GSK) Receives FDA Extended Priority Review for PROMACTA(R) NDA
-
Ligand (LGND) Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
-
Ligand Pharmaceuticals (LGND) Receives $1M Milestone Payment From GSK
-
King Pharmaceuticals (KG) Buys AVINZA Rights from Ligand Pharmaceuticals (LGND)
-
Ligand Pharmaceuticals (LGND) Earns Milestone Payment From Wyeth (WYE)
-
LGND Earns $2M Milestone Payment from GlaxoSmithKline
-
LGND Presents Positive Trial Data on Cancer Drug ONTAK
-
LGND Said Collaborator Drug Shows Encouraging Results
-
LGNDE Second Manufacturing Source for AVINZA Approved by FDA
-
FDA Asks LGNDE to Make Label Changes to AVINZA
-
LGNDE Earns $1.6M Milestone Payment form LLY
-
LGNDE Earned $1.5M Milestone Payment from TAP Pharmaceutical
-
LGND Receives $1M Milestone Payment from GSK
-
LGND Says Pfizer Submits SNDA for Lasofoxifene
Back to LGND Stock Lookup
